Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [4] - The company is listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [4] Recent Developments - The Chief Executive Officer, Steven Lydeamore, presented at the 21st Virtual Investor Summit Microcap Event on November 21, 2024 [1] - A copy of the presentation is available on the company's website [2] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting travelers' diarrhea, which is caused by pathogenic bacteria [5] - Travelan® is a highly purified tabletized preparation of hyperimmune bovine antibodies and is indicated for reducing the risk of travelers' diarrhea and minor gastrointestinal disorders in Australia and Canada [5] - In the U.S., Travelan® is marketed as a dietary supplement for digestive tract protection [5] Technology Platform - Immuron's proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, allowing for the production of highly specific immunoglobulins to any enteric pathogen [7] - The platform technology enables the development of medicines across a wide range of infectious diseases by blocking viruses or bacteria at mucosal surfaces [7] Research and Development - IMM-124E, developed using Immuron's platform technology, is produced from the colostrum of immunized cattle and targets enterotoxigenic E. coli (ETEC) [8][9] - IMM-529 is being developed as an adjunctive therapy for the prevention and treatment of recurrent Clostridioides difficile infection (CDI) [12] - The unique three-target approach of IMM-529 has shown promising results in pre-clinical models, including prevention of primary disease (80% efficacy), protection against disease recurrence (67% efficacy), and treatment of primary disease (78.6% efficacy) [14]